Related Experiment Videos
Foamy virus--adenovirus hybrid vectors
M Picard-Maureau1, F Kreppel, D Lindemann
1Institut für Virologie und Immunbiologie, Universität Würzburg, Germany.
Gene Therapy
|January 16, 2004
Summary
New hybrid vectors combine high-capacity adenovirus and foamy virus (FV) features for stable gene delivery. HC-FAD-2 vectors show promise for in vivo applications due to efficient, stable transduction.
Area of Science:
- * Molecular Biology
- * Gene Therapy
- * Virology
Background:
- * Adenovirus vectors (AdV) are widely used but lack genomic integration.
- * Prototypic foamy viruses (FV) are retroviruses with unique replication and no known pathogenicity.
- * Hybrid vectors aim to combine AdV's high capacity with FV's integration capability.
Purpose of the Study:
- * To create and characterize hybrid vectors expressing FV in an AdV backbone.
- * To evaluate the in vitro performance of two hybrid vector types (HC-FAD-7 and HC-FAD-2).
- * To assess the potential for stable transgene expression and genomic integration.
Main Methods:
- * Construction of hybrid vectors (HC-FAD-7, HC-FAD-2) with FV expression regulated by a tetracycline system.
- * Production of hybrid vectors at high titers (approx. 10^10 infectious units/ml).
- * Southern blotting to confirm host cell genomic integration; transduction efficiency assessed via Southern blot and flow cytometry.
Main Results:
- * Hybrid vectors successfully generated host cell genomic integrants.
- * HC-FAD-7 showed low efficiency for stable transgene expression.
- * HC-FAD-2 achieved approximately 70% stable transduction in a secondary round at MOI 100.
Conclusions:
- * Hybrid vectors integrating FV into AdV backbones are feasible.
- * HC-FAD-2 demonstrates superior efficiency for stable gene transfer compared to HC-FAD-7.
- * HC-FAD-2 vectors are suitable for in vivo gene therapy applications due to their safety profile and transduction efficiency.